FindTrial
Sign In

How pharmacist education can help patients using prescribed drug reduce side effects: A study at a teaching hospital.

Impact Of Clinical Pharmacist Developed Educational Tool And Counselling on ADR s of SGLT2 Inhibitor Users at Tertiary Care Teaching Hospital: A Randomized Controlled Study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/095797
Enrollment
200
Registered
2025-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N181- Chronic kidney disease, stage 1 Health Condition 2: N182- Chronic kidney disease, stage 2 (mild) Health Condition 3: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 4: N184- Chronic kidney disease, stage 4 (severe) Health Condition 5: I210- ST elevation (STEMI) myocardial infarction of anterior wall Health Condition 6: E115- Type 2 diabetes mellitus with circulatory complications Health Condition 7: E112- Type 2 diabetes mellitus with kidney complicati

Interventions

Intervention1: Pharmacist intervention: Minimizing and Preventing ADR through Patient counselling every month for 3 months and handing out educational tool at the first intervention(card). Control Int

Sponsors

Dr Anushree Deshpande
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients aged more than or equal to 18 years. 2) The literate patients diagnosed with any cardiovascular disease, T2DM and CKD. 3) All patients on SGLT2 inhibitors, either as monotherapy or in combination with other drugs. 4) Patients willing to provide written consent for participation in the study.

Exclusion criteria

Exclusion criteria: 1) The patient with known history of Genital infections and UTI before taking SGLT2i. 2) Patient with incomplete demographics and laboratory findings. 3) Patients with T1 DM, Immunocompromised like STDs, serious complications like Cancer, terminally ill, cognitive impaired patients. etc. 4) Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Awareness on safe use of SGLT2 inhibitors.Timepoint: 1 year—

Secondary

MeasureTime frame
Reduction in incidence & severity of ADRs (based on WHO & Hartwig Siegel scales).Timepoint: every 30 days for 3 months;Improved patient adherence to sick day rules & hygiene practices.Timepoint: every 30 days for 3 months;Validate use of pharmacist-developed educational tool (card) in chronic disease management.Timepoint:—

Countries

India

Contacts

Public ContactAdvita Ganachari

KLE College of Pharmacy, Belagavi

anushreedeshpande@klepharm.edu8792998483

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026